Yousif Capital Management LLC Sells 655 Shares of Lantheus Holdings, Inc. $LNTH

Yousif Capital Management LLC decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 23,894 shares of the medical equipment provider’s stock after selling 655 shares during the period. Yousif Capital Management LLC’s holdings in Lantheus were worth $1,956,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in LNTH. TD Asset Management Inc increased its stake in shares of Lantheus by 1,028.0% in the first quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider’s stock worth $66,623,000 after buying an additional 622,100 shares during the period. Nuveen LLC purchased a new position in shares of Lantheus in the first quarter worth $55,941,000. Epoch Investment Partners Inc. purchased a new position in shares of Lantheus in the first quarter worth $35,548,000. Mackenzie Financial Corp increased its stake in shares of Lantheus by 129.2% in the first quarter. Mackenzie Financial Corp now owns 497,437 shares of the medical equipment provider’s stock worth $48,550,000 after buying an additional 280,381 shares during the period. Finally, Keybank National Association OH increased its stake in shares of Lantheus by 87.5% in the first quarter. Keybank National Association OH now owns 576,835 shares of the medical equipment provider’s stock worth $56,299,000 after buying an additional 269,146 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Lantheus

In related news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This trade represents a 49.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rajiv A. Patel sold 3,365,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,812,000 shares of company stock valued at $382,427,380 in the last three months. Corporate insiders own 1.50% of the company’s stock.

Lantheus Stock Down 1.3%

Shares of NASDAQ:LNTH opened at $55.60 on Friday. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $118.21. The firm has a market capitalization of $3.78 billion, a P/E ratio of 14.79 and a beta of 0.09. The stock has a 50 day moving average price of $53.91 and a 200-day moving average price of $73.12. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm had revenue of $92.51 million during the quarter. As a group, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on LNTH shares. JMP Securities reduced their target price on Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 7th. Weiss Ratings reissued a “hold (c-)” rating on shares of Lantheus in a research report on Wednesday, October 8th. The Goldman Sachs Group set a $77.00 price objective on shares of Lantheus and gave the company a “neutral” rating in a research report on Wednesday, October 8th. Mizuho reduced their price objective on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. Finally, Truist Financial set a $63.00 price objective on shares of Lantheus and gave the company a “hold” rating in a research report on Monday, August 11th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $74.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.